Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
NCT02439411 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135
Last updated 2019-12-02
Summary
The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.
Conditions
- Malignant Melanoma Stage IV
- Malignant Melanoma Stage IIIc
Interventions
- DRUG
-
Trametinib
Sponsors & Collaborators
- collaborator INDUSTRY
-
Grupo Español Multidisciplinar de Melanoma
lead OTHER
Principal Investigators
-
Salvador Martín Algarra, M.D., Ph.D. · Clinica Universidad de Navarra
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-03
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- Spain
Study Locations
More Related Trials
-
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
NCT06557291 ·Status: COMPLETED
-
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
NCT02039947 ·Status: COMPLETED ·Phase: PHASE2
-
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
NCT05171374 ·Status: UNKNOWN
-
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
NCT03551626 ·Status: COMPLETED ·Phase: PHASE3
-
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
NCT02296996 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
NCT02083354 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
NCT02027961 ·Status: COMPLETED ·Phase: PHASE1
-
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
NCT02410863 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
NCT02535078 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
NCT02583516 ·Status: COMPLETED ·Phase: PHASE2
-
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
NCT03352947 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
NCT04961619 ·Status: COMPLETED
-
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
NCT04184518 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT02967692 ·Status: TERMINATED ·Phase: PHASE3
-
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
NCT05756556 ·Status: SUSPENDED ·Phase: PHASE2
-
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
NCT01614301 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
NCT05714371 ·Status: COMPLETED
-
Study of Talabostat in Advanced Melanoma
NCT00083239 ·Status: COMPLETED ·Phase: PHASE2
-
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NCT03272464 ·Status: TERMINATED ·Phase: PHASE1
-
Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
NCT06774989 ·Status: RECRUITING
-
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
NCT03605771 ·Status: RECRUITING
-
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
NCT03178851 ·Status: COMPLETED ·Phase: PHASE1
-
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
NCT01280565 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2